Immunodepletion with Hypoxemia: A Potential High Risk Subtype of Coronavirus Disease 2019

Yu, Lilei; Tong, Yongqing; Shen, Gaigai; Fu, Aisi; Lai, Yanqiu; Zhou, Xin; Yuan, Yuan; Wang, Yuhong; Pan, Yuanfeng; Yu, Zhiyao; Liu, Tiangang; Hong, Jiang

doi:10.1101/2020.03.03.20030650

Cited by 53 publications

(66 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The infectious form of the virus was even identified several times, suggesting that the orofecal route is a mode of contamination (1). The gut involvement might explain the wide variation in viral load from one test to another in the same person as if the virus were hiding there (2). Chinese researchers have investigated changes in the microbiota in the patients who have died for COVID-19 infection.…”

Section: Introductionmentioning

confidence: 99%

Challenges in the Management of SARS-CoV2 Infection: The Role of Oral Bacteriotherapy as Complementary Therapeutic Strategy to Avoid the Progression of COVID-19

et al. 2020

View full text Add to dashboard Cite

Background: Gastrointestinal disorders are frequent in COVID-19 and SARS-CoV-2 has been hypothesized to impact on host microbial flora and gut inflammation, infecting intestinal epithelial cells. Since there are currently no coded therapies or guidelines for treatment of COVID-19, this study aimed to evaluate the possible role of a specific oral bacteriotherapy as complementary therapeutic strategy to avoid the progression of COVID-19. Methods: We provide a report of 70 patients positive for COVID-19, hospitalized between March 9th and April 4th, 2020. All the patients had fever, required non-invasive oxygen therapy and presented a CT lung involvement on imaging more than 50%. Forty-two patients received hydroxychloroquine, antibiotics, and tocilizumab, alone or in combination. A second group of 28 subjects received the same therapy added with oral bacteriotherapy, using a multistrain formulation. Results: The two cohorts of patients were comparable for age, sex, laboratory values, concomitant pathologies, and the modality of oxygen support. Within 72 h, nearly all patients treated with bacteriotherapy showed remission of diarrhea and other symptoms as compared to less than half of the not supplemented group. The estimated risk of developing respiratory failure was eight-fold lower in patients receiving oral bacteriotherapy. Both the prevalence of patients transferred to ICU and mortality were higher among the patients not treated with oral bacteriotherapy. d'Ettorre et al. Bacteriotherapy in Treating COVID-19 Conclusions: A specific bacterial formulation showed a significant ameliorating impact on the clinical conditions of patients positive for SARS-CoV-2 infection. These results also stress the importance of the gut-lung axis in controlling the COVID-19 disease.

show abstract

Section: Introductionmentioning

confidence: 99%

Challenges in the Management of SARS-CoV2 Infection: The Role of Oral Bacteriotherapy as Complementary Therapeutic Strategy to Avoid the Progression of COVID-19

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The elevated IL-6 was significantly related to the clinical manifestation of severe type patients [34]. An analysis of dynamic characteristics of host immune system in 3 critical cases showed that hypoxemia severity was closely related with host immune cell levels [35], and the lymphocytopenia and cytotoxicity may be the result of SARS-CoV-2 infection [36]. An observation showed that after SARS-CoV-2 infection, CD4 + T lymphocytes are rapidly activated to become pathogenic T helper (Th) 1 cells and generate cytokines including GM-CSF.…”

Section: Pathogenesis Of Cytokine Release Syndrome Induced By Sars-cov-2mentioning

confidence: 92%

Advances in COVID-19: the virus, the pathogenesis, and evidence-based control and therapeutic strategies

2020

View full text Add to dashboard Cite

128 665 confirmed cases and 5536 deaths have been reported, with 16 498 new cases and 817 new deaths occurring in last 24 hours. Therefore, the world should work together to fight against this pandemic. Here, we review the recent advances in COVID-19, including the insights in the virus, the responses of the host cells, the cytokine release syndrome, and the therapeutic approaches to inhibit the virus and alleviate the cytokine storm. By sharing knowledge and deepening our understanding of the virus and the disease pathogenesis, we believe that the community can efficiently develop effective vaccines and drugs, and the mankind will eventually win this battle against this pandemic.

show abstract

“…One can speculate that the decrease in ACE2 availability during SARS-COV-2 infection is enough to alter the composition of the gut microbiota. Recent pilot studies suggest gut microbiota alterations during SARS-CoV-2 infection (Yu et al, 2020;Gu et al, 2020b;Zuo et al, 2020). In a cohort of 30 COVID-19 patients (fecal sample analysis using 16S rRNA gene sequencing), infection was associated with a significant decrease of bacterial diversity and abundance (Gu et al, 2020b).…”

Section: Ace2 Dysfunction Alters the Composition Of The Gut Microbiotamentioning

confidence: 99%

Potential Causes and Consequences of Gastrointestinal Disorders during a SARS-CoV-2 Infection

2020

View full text Add to dashboard Cite

Coronaviruses cause several human diseases, including severe acute respiratory syndrome. The global coronavirus disease 2019 (COVID-19) pandemic has become a huge threat to humans. Intensive research on the pathogenic mechanisms used by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is urgently needed-notably to identify potential drug targets. Clinical studies of patients with COVID-19 have shown that gastrointestinal disorders appear to precede or follow the respiratory symptoms. Here, we review gastrointestinal disorders in patients with COVID-19, suggest hypothetical mechanisms leading to gut symptoms, and discuss the potential consequences of gastrointestinal disorders on the outcome of the disease. Lastly, we discuss the role of the gut microbiota during respiratory viral infections and suggest that targeting gut dysbiosis may help to control the pathogenesis of COVID-19. Coronaviruses are enveloped RNA viruses containing a large (25 to 32 kb), single-stranded, positive-sense RNA genome. These viruses circulate continuously in human populations and generally cause mild respiratory diseases, including the common cold. In contrast, the zoonotic severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV) cause severe respiratory diseases and are associated with a high mortality rate when they spread to humans (Fehr et al., 2017). No specific antiviral drugs or vaccines have been approved for combating infections by SARS and MERS. In late 2019, a new infectious respiratory disease (now termed coronavirus disease 2019 [COVID-19]) emerged in Wuhan, China (Wang et al., 2020a; Zhu et al., 2020). This disease spread rapidly across China and to other countries. The World Health Organization recently declared the COVID-19 outbreak to be a pandemic. SARS-CoV-2 is the etiological agent of COVID-19 (Zhu et al., 2020). A phylogenetic analysis has shown that SARS-CoV-2 is most closely related to SARS-CoV (nucleotide similarity: 89.1%). COVID-19 is characterized by acute pathological outcomes, including pneumonia and acute respiratory distress syndrome (ARDS), and has a substantial mortality rate (Chen et al., 2020). ARDS during a SARS-CoV-2 infection is also associated with dysregulation of cytokine production, barrier leakage, and organ dysfunction. COVID-19 is more severe in individuals with comorbidities (diabetes mellitus, cardiovascular diseases, and hypertension) and in the elderly (Guan et al., 2020; Wu and McGoogan, 2020).

show abstract

Immunodepletion with Hypoxemia: A Potential High Risk Subtype of Coronavirus Disease 2019

Abstract: Background The outbreak of COVID-2019 is becoming a global public health

Cited by 53 publications

References 10 publications

Challenges in the Management of SARS-CoV2 Infection: The Role of Oral Bacteriotherapy as Complementary Therapeutic Strategy to Avoid the Progression of COVID-19

Challenges in the Management of SARS-CoV2 Infection: The Role of Oral Bacteriotherapy as Complementary Therapeutic Strategy to Avoid the Progression of COVID-19

Advances in COVID-19: the virus, the pathogenesis, and evidence-based control and therapeutic strategies

Potential Causes and Consequences of Gastrointestinal Disorders during a SARS-CoV-2 Infection

Contact Info

Product

Resources

About